THOR-707 Combination Therapy for Cancer

(HAMMER Trial)

This trial aims to test a new cancer treatment called THOR-707, both alone and with other therapies, to evaluate its safety and effectiveness against tumors. Researchers seek to determine the best dose patients can tolerate and assess its potential to shrink tumors. The trial includes different groups: some receive THOR-707 alone, while others receive it with additional treatments, such as checkpoint inhibitors, which help the immune system attack cancer. This trial targets individuals with advanced or metastatic solid tumors who have tried other treatments without success or have limited options. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering patients a chance to be among the first to receive this new therapy.

The trial protocol does not clearly specify if you need to stop taking your current medications. However, you cannot have had certain treatments like radiotherapy or systemic anti-cancer therapy shortly before starting the trial. It's best to discuss your specific medications with the trial team.

Research shows that THOR-707 is under study for its safety in humans, both alone and with other treatments. Early studies suggest that THOR-707 is generally well-tolerated, though it can have side effects like many treatments.

Previous studies found some side effects when used alone, but they were mostly manageable, meaning they were not severe for most people.

When combined with a checkpoint inhibitor (a drug that helps the immune system fight cancer), safety studies found a similar pattern. Side effects occurred but were usually mild and treatable.

In combination with an anti-EGFR antibody (a drug that blocks cancer growth signals), THOR-707 also showed a tolerable safety profile. Again, side effects were present but mostly manageable.

Researchers are excited about THOR-707 because it offers a unique approach to treating advanced or metastatic cancers. Unlike traditional treatments like chemotherapy, which indiscriminately attack both cancerous and healthy cells, THOR-707 is a pegylated cytokine that selectively stimulates the immune system to target and destroy cancer cells. By enhancing the body's own immune response, THOR-707 aims to achieve similar or improved effectiveness with potentially fewer side effects. Additionally, when combined with checkpoint inhibitors or anti-EGFR antibodies, THOR-707 could amplify the immune response further, offering a promising new strategy for challenging cancers like metastatic melanoma and solid tumors.

Research shows that THOR-707 may help treat cancer. Studies have found that THOR-707 boosts the immune system by increasing CD8+ T cells, which play a crucial role in fighting tumors. In this trial, participants will receive THOR-707 either as a monotherapy or combined with other treatments. Some participants will receive THOR-707 with checkpoint inhibitors, which studies suggest may enhance its effectiveness. Early studies also indicate that THOR-707 can improve cancer treatment without causing the severe side effects seen with some older drugs. Overall, these findings suggest THOR-707 could be a promising treatment option for people with advanced cancers.²³⁶⁷⁸